Every other GH peptide is sold for research. This one went through full trials and FDA review. That evidence is real — but it's narrower than the marketing implies.
Instant PDF download. Yours to keep — no subscription.
Get the guide — $10.99 →Instant PDF delivery · Secure Stripe checkout · Research-only, not medical advice
The only FDA-trialled GH peptide — the real evidence, and its real limits.
Tesamorelin is the one growth-hormone peptide with real human trial data — full Phase 2 and Phase 3, FDA-reviewed. That's a far higher bar than anything else in the category.
It raises your own IGF-1 by signalling your pituitary, so your natural safety brakes stay on. It targets visceral fat specifically — the deep fat around your organs — and a controlled trial even showed better memory and executive function.
But "FDA-approved" is doing narrower work than the marketing implies: it's approved for HIV-associated lipodystrophy only. Every other use is off-label. This guide keeps that distinction sharp — and spells out the one non-optional safety step.
A complete, plain-English breakdown — with the FDA approval framed for exactly what it is.
The only GH peptide with real Phase 2 and Phase 3 data
Visceral fat vs the pinchable layer — what it actually targets
How it raises your own IGF-1 — and why that keeps your brakes on
The cognition data almost nobody mentions
The cost reality: brand-name vs research-grade, same molecule
The required IGF-1 bloodwork, and the week-1 bloating
Tesamorelin is the rare case where the headline numbers are human trial data. Where the use is off-label, we say so.
The one GH peptide with real human trial data — full Phase 2 and Phase 3, FDA-reviewed. A far higher bar than anything else in the category.
15–18% visceral-fat reduction in 26 weeks (412-person approval trial) — the deep fat around your organs, not the pinchable layer diet already handles.
Raises your own IGF-1 ~80% on average (up to 181%) by signalling your pituitary — it doesn't inject hormone from outside, so your natural safety brakes stay on.
Measurably better memory and executive function in a 152-adult, 20-week controlled trial — the benefit almost nobody mentions.
Brand-name Egrifta runs $2,400–6,000+/month, but the identical research-grade molecule can be ~$100–250/month. The gap is paperwork, not chemistry.
The one non-optional safety step — IGF-1 bloodwork — spelled out, plus how to get through the week-1 bloating most people quit over.
You could ask an AI about tesamorelin and get a confident answer in seconds. It'll also invent citations, quietly blend animal results into human ones, and round the flattering numbers up. A good part of this industry runs on exactly that.
Every Lumen guide is the opposite: a person reads the primary research, writes it in plain English, and edits it line by line before it ships — and nothing goes in that can't be traced to a real source.
Hand-researched and edited. Written and checked from primary sources by a person — not an unread, auto-generated dump.
Every claim cited and labelled. Each figure shows the evidence behind it — human, animal, mechanism, or trial data.
Written in plain English. The mechanism, the maths and the protocol, made readable — no pharmacology degree required.
No reviews we can't verify. We'd rather leave the space empty than fake a testimonial.
Instant delivery, yours to keep. A downloadable PDF the moment you check out — no account, no subscription.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy only. Every other use (visceral fat, body composition, cognition) is off-label. The trial data is real, but "FDA-approved" is not the same claim as "approved for what you're about to use it for." This page is for research and educational use only.
Instant PDF delivery. Real trial data, the honest cost spread, and the bloodwork you can't skip.
Get the guide — $10.99 →One-time · instant download · research & educational use only
Verified reviews from people who actually bought this guide.
New research drops and dosing updates, straight to your inbox. No spam, unsubscribe anytime.